Skip to content

Cardiovascular Magnetic Resonance Image Analysis and Mechanism Study for the Changes After Treatments for Primary Microvascular Angina Pectoris

Cardiovascular Magnetic Resonance Image Analysis and Mechanism Study for the Changes After Treatments for Primary Microvascular Angina Pectoris

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025319
Enrollment
Unknown
Registered
2019-08-23
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary microvascular angina

Interventions

1:conventional medical treatment (Aspirin 100mg QN, Atorvastatin 20mg QN, Isosorbide mononitrate tablet 40mg QD, Metoprolol ZOK 47.5mg QD, Perindopril 4mg QD)
2:conventional medical treatment and diltiazem
3:conventional medical treatment and beraprost Sodium
4:conventional medical treatment and Nicodil

Sponsors

Hangzhou Red Cross Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 75 years; (1) Typical labor-type angina for at least half a year. (2) Electrocardiogram conventional 12-lead trace, ST-segment offset measurement 80 ms after J point. (3) Exercise flat test positive(ST-segment ischemic down-shift >= 0.01mm) or dynamic ECG monitoring showed at least one ST-segment ischemic down-shift >=0.01 mm. (4) The left ventricular function of the echocardiogram was normal, and the left ventricular ejection fraction (LVEF) was >55%. (5) Coronary angiography showed normal or near normal (contrast findings suggest normal or irregular epicardial coronary vessel wall, mild stenosis of lumen discontinuity, stenosis <20%), no spontaneous coronary artery spasm Performance, TIMI blood flow 1-2 patients. (6) CMR confirmed the presence of coronary microcirculation.

Exclusion criteria

Exclusion criteria: (1) Organic heart disease including coronary artery spasm, coronary artery bridge, primary cardiomyopathy, congenital heart disease, valvular heart disease, hypertrophic cardiomyopathy, pulmonary heart disease, hypertensive heart disease; (2) Myocardial injury: including myocarditis, systemic and myocardial damage; (3) Clear history of myocardial infarction, coronary intervention, or coronary artery bypass grafting; (4) Arrhythmia requiring drug control; (5) Complete left bundle branch block, II and III degree atrioventricular block, sick sinus syndrome; (6) Severe congestive heart failure; (7) Malignant tumors; (8) Other diseases such as lung, esophagus, and aortic dissection that can cause chest pain; (9) Severe liver and kidney dysfunction; (10) Patients with acute or chronic inflammatory diseases and severe trauma; (11) Endocrine system diseases; (12) Anemia; (13) Peripheral vascular disease; (14) Active bile duct disease; (15) Ethanol intake; (16) Magnetic resonance examination for contraindicated patients; (17) Those who cannot adhere to the drugs; (18) Pregnancy and lactation women.

Design outcomes

Primary

MeasureTime frame
cardiovascular magnetic resonance;von Willebrand facto;homocysteine;

Countries

China

Contacts

Public ContactQi Huang

Hangzhou Red Cross Hospital

huanqqi1021@163.com+86 13588740500

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026